Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Kidney Transplant Recipient with Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Secondary to COVID-19 Pneumonia: A Case Report

Mohammed Somaili*, Hanadi Abu-aishah, Wejdan Haidar, Shorooq Hamzi, and Saad Khubrany
Internal Medicine Department, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia

ABSTRACT

Background. Currently, COVID-19 is becoming one of the most common causes of viral pneumonia worldwide. In the medical literature, very few case reports describe the association between COVID-19 and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in kidney transplant patients.

Methods. A 74-year-old immunocompromised man post–kidney transplant presented with nonspecific symptoms consisting of fatigue, malaise, and anorexia. He was also found to have hyponatremia in the context of pulmonary insults. SIADH in the setting of COVID-19 pneumonia was diagnosed after exclusion of other causes of hyponatremia. He was treated for COVID-19 pneumonia with antiviral therapy, secondary bacterial infection prophylaxis, dexamethasone and ventilatory support in addition to modification of antirejection medications.

Results. The patient has improved and his serum sodium normalized with management of primary insult.

Conclusions. SIADH should be suspected in transplant patients with COVID-19 pneumonia once they develop hyponatremia. The decision of intravenous fluid administration should be taken carefully in these settings.

THE current COVID-19 pandemic, caused by SARS-CoV-2, is a serious public health concern worldwide [1].

The clinical presentation of COVID-19 ranges from mild disease with upper respiratory tract symptoms to a severe form of the disease with pneumonia and organ failure. Pulmonary manifestations of COVID-19 include fever, fatigue, shortness of breath, and cough [2].

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is characterized by impaired water excretion secondary to the inability to inhibit antidiuretic hormone (ADH) secretion [3]. SIADH, characterized by uncontrolled release of ADH, occurs when the total body water content exceeds urinary excretion, commonly referred to as euvolemic dilutional hyponatremia [3,4].

The mechanism underlying hyponatremia in patients with COVID-19 is excessive release of inflammatory cytokines, including interleukin (IL)-1β, IL-6, and the tumor necrosis factor. IL-6 triggers hypothalamic arginine vasopressin production with consequent hyponatremia [5,6].

In addition to infections, SIADH may occur in neurologic disorders including head injury and stroke, as well as paraneoplastic syndromes and may be associated with the administration of medications such as tricyclic antidepressants and selective serotonin reuptake inhibitors [7–9].

SIADH should be considered in the differential diagnosis in patients with hyponatremia (serum sodium levels <135 mmol/L) associated with plasma hypo-osmolality, urine hyperosmolality (>100 mosmol/kg), and high urinary sodium (>40 mEq/L). Notably, the serum potassium level is normal, no acid-base disturbance is observed, and the serum uric acid level is frequently low in patients with SIADH [4,8].

A systematic review and meta-analysis reported that SIADH-induced hyponatremia was associated with longer length of
intensive care unit (ICU) stay and was shown to be associated with a high mortality rate in patients with COVID-19. The prognostic value of this finding remains unclear and requires further investigation [10]. Few case reports have described COVID-19–associated SIADH and hyponatremia. We present a case of hyponatremia secondary to SIADH in a patient with COVID-19 pneumonia and a history of kidney transplantation.

CASE PRESENTATION
A 76-year-old man with a medical history of living-related kidney transplant in 2011, type 2 diabetes mellitus, and hypertension presented to the emergency department with nonspecific symptoms, including malaise, headache, poor oral intake, and fatigue. He denied a history of fever, confusion, seizures, chest, or gastrointestinal symptoms and denied the administration of any new medications or changes to his usual prescription. He had recently received the first dose of the COVID-19 vaccine. Current medications included prednisone, tacrolimus, mycophenolate mofetil, nifedipine, losartan, metoprolol, atorvastatin, glipizide, Januvia/Metformin, magnesium oxide, and omeprazole.

Physical examination showed normal vital signs, and volume status evaluation showed euvolemia. Systemic evaluation including chest and neurologic examination was unremarkable.

Initial chemistry, urinalysis and brain computed tomography were unremarkable (Table 1). The patient was admitted to the hospital for appropriate hydration, with a tentative diagnosis of mildly symptomatic hyponatremia secondary to poor oral intake. We initiated intravenous fluid (IVF) administration, and a Foley catheter was inserted to monitor fluid status. Blood work obtained 6 hours later showed worsening hyponatremia with a serum sodium level of 120 mEq/L but normal renal function; therefore, the patient underwent workup for hyponatremia (Table 2).

The patient’s condition worsened 24 hours later, with progressive shortness of breath and low-grade fever but normal blood pressure. Arterial blood gas evaluation results were consistent with severe hypoxemia (type 1 respiratory failure) with anion gap metabolic acidosis. Chest radiography revealed bilateral diffuse interstitial infiltrates (Fig 1). We performed reverse transcriptase-polymerase chain reaction testing for COVID-19, and the patient was transferred to the ICU for monitoring and respiratory support after discontinuation of IVF. The patient was tentatively diagnosed with respiratory failure secondary to COVID-19 pneumonia. Hyponatremia was likely secondary to SIADH in the setting of chest infection, which was supported by the laboratory test results. Despite trials of continuous positive airway pressure, the patient’s respiratory status continued to deteriorate, which eventually necessitated intubation. The patient also received full empirical therapy for suspected COVID-19 pneumonia, including dexamethasone, favipiravir, tocilizumab, and nebulizers, secondary bacterial infection prophylaxis, and modifications to his anti-rejection medications. He remained hemodynamically stable and did not require inotropic or vasopressor support. The patient’s COVID-19 test showed positive results, 12 hours later. The patient’s respiratory status improved slightly the following day, and ventilator settings were adjusted to wean the patient from mechanical ventilatory support. He remained intubated in the ICU for 5 days.

Table 1. Initial Laboratory Test Results

| Laboratory Studies          | Value       |
|----------------------------|-------------|
| WBC count (× 10⁹ /μL)      | 8,500       |
| Lymphocytes                | 35%         |
| Neutrophils                | 45%         |
| Serum hemoglobin           | 13 g/dL     |
| Platelets (× 10⁹ /μL)      | 230,000     |
| Serum urea                 | 10 mg/dL    |
| Serum creatinine           | 0.9 mg/dL   |
| Serum potassium            | 4.4 mEq/L   |
| Serum sodium               | 123 mEq/L   |
| Serum uric acid            | 3 mg/dL     |

Table 2. Follow-up Laboratory Test Results

| Laboratory Studies                        | Value       |
|-------------------------------------------|-------------|
| Serum sodium                              | 120 mEq/L   |
| Serum potassium                           | 4.4 mEq/L   |
| Urinary sodium                            | 67 mmol/L   |
| Serum osmolality                          | 230 mosm/kg |
| Urine osmolality                          | 590 mosm/kg |
| Serum thyroid stimulating hormone         | Normal      |
| Serum cortisol                            | Normal      |

WBC, white blood cells.

Fig 1. Chest radiograph (anteroposterior view) showing bilateral diffuse interstitial infiltrates in a patient with COVID-19 pneumonia and a history of kidney transplantation.
His condition gradually improved, and he was successfully extubated and transferred to the general ward following stabilization of his general condition. The patient’s kidney function remained normal throughout admission, and serum sodium level improved gradually with a parallel improvement in his respiratory status (Table 3).

DISCUSSION

Several studies have reported pneumonia associated with SIADH [11−13]; however, few case reports have discussed SIADH secondary to COVID-19 pneumonia [14,15]. To our knowledge, this is the first case report that describes SIADH-induced hyponatremia in a patient with SARS-CoV-2 infection and a history of kidney transplantation.

Our patient was an elderly man with a history of long-standing diabetes and hypertension and kidney transplantation, who received potent immunosuppressant agents including mycophenolate mofetil. Therefore, the patient was not administered the complete COVID-19 vaccine course.

Immunocompromised patients are known to show greater susceptibility to COVID-19 breakthrough infections [16,17]. Interestingly, the highest risk was observed among recipients of solid organ transplant [16−18].

Furthermore, immunocompromised patients tend to present with atypical clinical manifestations, as observed in the present case [17,19]. Diagnosis of COVID-19 infection was confirmed using reverse transcriptase-polymerase chain reaction testing, and pneumonia was confirmed based on chest radiography findings, which revealed diffuse bilateral pulmonary infiltrates in our patient.

SIADH should be suspected in patients with hyponatremia (serum sodium levels <135 mmol/L), and low plasma osmolality (<280 mosmol/kg), high urine osmolality (>100 mosmol/kg), and high urinary sodium levels (>20 mmol/L) are useful for diagnostic confirmation [3,20].

In the present case, laboratory test results revealed severe hyponatremia (serum sodium 120 mEq/L), serum osmolality 230 mosmol/kg, urine osmolality 590 mosmol/kg, high urinary sodium levels (67 mmol/L), and low serum uric acid levels, all of which were consistent with diagnosis of SIADH [3,4].

Habib et al observed that SIADH may often be an initial presentation of COVID-19 infection [21]. COVID-19-induced hyponatremia is attributed to sepsis and cytokine storm (excessive IL-6 release), which consequently activates the hypothalamic-pituitary-adrenal axis and upregulates arginine vasopressin expression [5,6].

A variety of medications can cause SIADH-induced hyponatremia [7−9]. However, no medication administered by our patient is reported to cause hyponatremia or SIADH.

Severe hyponatremia can precipitate a variety of neurologic symptoms, including lethargy, drowsiness, seizures, and loss of consciousness [19,22] and may even result in brain stem herniation secondary to cerebral edema. Moreover, rapid correction of hyponatremia can lead to serious neurologic insult such as the osmotic demyelination syndrome [23]. Fortunately, supportive management in the ICU and optimal treatment of the primary injury (pneumonia) led to gradual improvement in our patient’s condition, and his serum sodium levels returned to the normal range.

Hyponatremia observed in recipients of kidney transplants may be multifactorial in origin [24,25]. Patients who undergo solid organ transplantation show greater susceptibility to infections and may be predisposed to SIADH-induced hyponatremia. Poor oral intake may contribute to hyponatremia in these patients and may lead to hypovolemic hypo-osmolar hyponatremia [16−18]. This condition is often therapeutically challenging. IVF administration can worsen hyponatremia in patients with SIADH owing to the desalination phenomenon [26,27], although IVF is known to improve serum sodium levels in patients with hypovolemia. IVF administration initially led to worsening of serum sodium levels in our patient; however, these improved gradually parallel with improvement in the patient’s respiratory status, all of which support the diagnosis of SIADH-induced hyponatremia in this case.

CONCLUSIONS

COVID-19 is associated with the development of SIADH; therefore, this condition should be considered in the differential diagnosis in patients with hyponatremia. Administration of IVF warrants cautious decision-making in these settings to avoid worsening of hyponatremia. Moreover, vaccination of immunocompromised patients (such as those with a history of kidney transplant) plays a key role in reducing the transmission of the virus and controlling the COVID-19 pandemic.

REFERENCES

[1] Centers for Disease Control and Prevention. CDC. Disease or condition of the week - COVID-19, https://www.cdc.gov/dowtw/covid-19/index.html; 2021 [accessed 03.03.22].
[2] da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr 2020;26:1−6.
[3] Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35:1495–9.
[4] Weitzman RE, Kleeman CR. The clinical physiology of water metabolism: part III: the water depletion (hyperosmolar) and water excess (hyposmolar) syndromes. West J Med 1980;132:16.
[5] Journal of Immunological Sciences. Cytokine storm and its implication in coronavirus disease 2019 (COVID-19), https://www.
immunologyresearchjournal.com/articles/cytokine-storm-and-its-impli-
cation-in-coronavirus-disease-2019-covid-19.html; 2020 [accessed
03.03.2022].

[6] Nikbakht F, Mohammadkhanizadeh A, Mohammadi E. How
does the COVID-19 cause seizure and epilepsy in patients? The poten-
tial mechanisms. Mult Scler Relat Disord 2020;46:102535.

[7] Shepshelovich D, Leibovitch C, Klein A, Zoldan S, Milo G,
Shohat T, et al. The syndrome of inappropriate antidiuretic hormone
secretion: distribution and characterization according to etiologies. Eur
J of Intern Med 2015;26:819–24.

[8] Ferlito A, Rinaldo A, Devaney KO. Syndrome of inap-
propriate antidiuretic hormone secretion associated with head and neck
cancers: review of the literature. Ann Otol Rhinol Laryngol
1997;106:878–83.

[9] Chan TYK. Drug-induced syndrome of inappropriate antidiu-
retic hormone secretion. Drugs Aging 1997;11:27–44.

[10] Akbar MR, Pranata R, Wibowo A, Irvan Sibite TA, Martha
JW. The prognostic value of hyponatremia for predicting poor outcome
in patients with COVID-19: a systematic review and meta-analysis.
Front Med (Lausanne) 2021;8:666949.

[11] Hannon MJ, Thompson CJ. The syndrome of inappropriate
antidiuretic hormone: prevalence, causes and consequences. Eur J
Endocrinol 2010;162:S5–12.

[12] Bowles KD, Brainard BM, Coleman KD. Syndrome of inap-
propriate antidiuretic hormone in a bulldog with aspiration pneumonia.
J Vet Intern Med 2015;29:972–6.

[13] Dhawan A, Narang A, Singh S. Hyponatraemia and the inap-
propriate ADH syndrome in pneumonia. Ann Trop Pediatr
1992;12:455–62.

[14] Gemcioglu E, Karabuga B, Ercan A, Erden A. A case of
inappropriate antidiuretic hormone secretion syndrome associated
with COVID-19 pneumonia. Acta Endocrinol (Buchar)
2020;16:110–1.

[15] Ravioli S, Niebuhr N, Ruchti C, Fluess E, Stockli T, Lindner
G. Syndrome of inappropriate antidiuresis in COVID-19 pneumonia:
report of two cases. Clin Kidney J 2020;13:461–2.

[16] Ejaz H, Alshrani A, Zafar A, Javed H, Junaid K, Abdalla AE,
et al. COVID-19 and comorbidities: deleterious impact on infected
patients. J Infect Public Health 2020;13:1833–9.

[17] Fishman JA, Grossi PA. Novel coronavirus-19 (COVID-19) in
the immunocompromised transplant recipient: #Flatteningthecurve. Am
J Transplant 2020;20:1765–7.

[18] Giovannoni G. Anti-CD20 immunosuppressive disease-modi-
fying therapies and COVID-19. Mult Scler Relat Disord 2020;41:
102135.

[19] Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla
R, Reddy PH. Emerging COVID-19 neurological manifestations:
present outlook and potential neurological challenges in COVID-19
pandemic. Mol Neurobiol 2021;58:4694–715.

[20] Peri A, Pirozzi N, Parenti G, Festuccia F, Menè P. Hyponatre-
temia and the syndrome of inappropriate secretion of antidiuretic hor-
mine (SIADH). J Endocrinol Invest 2010;33:671–82.

[21] Habib MB, Sardar S, Sajid J. Acute symptomatic hyponatremia
in setting of SIADH as an isolated presentation of COVID-19. IDCases
2020;21:e00859.

[22] Akbar MR, Pranata R, Wibowo A, Irvan Sibite TA, Martha
JW. The prognostic value of hyponatremia for predicting poor outcome
in patients with COVID-19: a systematic review and meta-analysis.
Front Med (Lausanne) 2021;8:666949.

[23] Giuliani C, Peri A. Effects of hyponatremia on the brain. J Clin
Med 2014;3:1163–77.

[24] Han SS, Han M, Park JY, An JN, Park S, Park S-K, et al. Post-
transplant hyponatremia predicts graft failure and mortality in kidney
transplantation recipients: a multicenter cohort study in Korea. PLoS
One 2016;11:e0156050.

[25] Tantisattamo E, Molnar MZ, Ho BT, Reddy UG, Dafoe DC,
Ichii H, et al. Approach and management of hypertension after kidney
transplantation. Front Med (Lausanne) 2020;7:229.

[26] Sahay M, Sahay R. Hyponatremia: A practical approach.
Indian J Endocrinol Metab 2014;18:760–71.

[27] Gilbert RD. Understanding and managing hyponatremia.
Pediatr Child Health 2010;20:261–5.